The global histone deacetylase (HDAC) inhibitor market is expected to grow at a CAGR of 7.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic diseases such as cancer and central nervous system disorders, which are associated with increased risk for developing neurodegenerative disorders.
The global HDAC inhibitor market is segmented on the basis of type into hydroxamates, cyclic peptides, aliphatic acids and benzamides. The hydroxamate segment accounted for the largest share in 2018 owing to its wide range of applications in various therapeutic areas such as cancer and central nervous system disorders diseases. The cyclic peptide segment is expected to grow at a CAGR of 8% during the forecast period owing to its high potency against various types of cancers including breast cancer and leukemia.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is driving the growth of the global Histone Deacetylase (HDAC) Inhibitor market.
- Increasing awareness about the benefits of HDAC inhibitors in treating various diseases is also driving the growth of this market globally.
- The increasing number of clinical trials for HDAC inhibitors in various therapeutic areas such as oncology, neurology, and cardiology are also driving this market globally.
- The availability of generic drugs for HDAC inhibitors is expected to provide a major opportunity for manufacturers.
Industry Growth Insights published a new data on “Histone Deacetylase (HDAC) Inhibitor Market”. The research report is titled “Histone Deacetylase (HDAC) Inhibitor Market research by Types (Hydroxamates, Cyclic Peptides, Aliphatic Acids, Benzamides), By Applications (Cancer, Central Nervous System Disorders, Other Diseases), By Players/Companies Celgene, Celleron Therapeutics, CrystalGenomics, Acetylon Pharmaceuticals, Novartis, Envivo Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Histone Deacetylase (HDAC) Inhibitor Market Research Report
By Type
Hydroxamates, Cyclic Peptides, Aliphatic Acids, Benzamides
By Application
Cancer, Central Nervous System Disorders, Other Diseases
By Companies
Celgene, Celleron Therapeutics, CrystalGenomics, Acetylon Pharmaceuticals, Novartis, Envivo Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
 Inhibitor Industry Outlook.svg)
Global Histone Deacetylase (HDAC) Inhibitor Market Report Segments:
The global Histone Deacetylase (HDAC) Inhibitor market is segmented on the basis of:
Types
Hydroxamates, Cyclic Peptides, Aliphatic Acids, Benzamides
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Central Nervous System Disorders, Other Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Celleron Therapeutics
- CrystalGenomics
- Acetylon Pharmaceuticals
- Novartis
- Envivo Pharmaceuticals
 Inhibitor Market Overview.svg)
Highlights of The Histone Deacetylase (HDAC) Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hydroxamates
- Cyclic Peptides
- Aliphatic Acids
- Benzamides
- By Application:
- Cancer
- Central Nervous System Disorders
- Other Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Histone Deacetylase (HDAC) Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitor Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Histone deacetylase inhibitors (HDACIs) are a type of drug that inhibits the activity of histone deacetylases. Histone deacetylases are enzymes that remove acetyl groups from histones, which can change the structure and function of proteins. HDACIs can help to prevent or reduce the effects of cancer by preventing tumor growth and metastasis.
Some of the major players in the histone deacetylase (hdac) inhibitor market are Celgene, Celleron Therapeutics, CrystalGenomics, Acetylon Pharmaceuticals, Novartis, Envivo Pharmaceuticals.
The histone deacetylase (hdac) inhibitor market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Histone Deacetylase (HDAC) Inhibitor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Histone Deacetylase (HDAC) Inhibitor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Histone Deacetylase (HDAC) Inhibitor Market - Supply Chain
4.5. Global Histone Deacetylase (HDAC) Inhibitor Market Forecast
4.5.1. Histone Deacetylase (HDAC) Inhibitor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Histone Deacetylase (HDAC) Inhibitor Market Size (000 Units) and Y-o-Y Growth
4.5.3. Histone Deacetylase (HDAC) Inhibitor Market Absolute $ Opportunity
5. Global Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Type
5.3.1. Hydroxamates
5.3.2. Cyclic Peptides
5.3.3. Aliphatic Acids
5.3.4. Benzamides
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Central Nervous System Disorders
6.3.3. Other Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Histone Deacetylase (HDAC) Inhibitor Demand Share Forecast, 2019-2029
9. North America Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Central Nervous System Disorders
9.4.3. Other Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Type
9.7.1. Hydroxamates
9.7.2. Cyclic Peptides
9.7.3. Aliphatic Acids
9.7.4. Benzamides
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Histone Deacetylase (HDAC) Inhibitor Demand Share Forecast, 2019-2029
10. Latin America Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Central Nervous System Disorders
10.4.3. Other Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Type
10.7.1. Hydroxamates
10.7.2. Cyclic Peptides
10.7.3. Aliphatic Acids
10.7.4. Benzamides
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Histone Deacetylase (HDAC) Inhibitor Demand Share Forecast, 2019-2029
11. Europe Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Central Nervous System Disorders
11.4.3. Other Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Type
11.7.1. Hydroxamaes
11.7.2. Cyclic Peptides
11.7.3. Aliphatic Acids
11.7.4. Benzamides
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Histone Deacetylase (HDAC) Inhibitor Demand Share, 2019-2029
12. Asia Pacific Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Central Nervous System Disorders
12.4.3. Other Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Type
12.7.1. Hydroxamates
12.7.2. Cyclic Peptides
12.7.3. Aliphatic Acids
12.7.4. Benzamides
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Histone Deacetylase (HDAC) Inhibitor Demand Share, 2019-2029
13. Middle East & Africa Histone Deacetylase (HDAC) Inhibitor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Central Nervous System Disorders
13.4.3. Other Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Histone Deacetylase (HDAC) Inhibitor Market Size and Volume Forecast by Type
13.7.1. Hydroxamates
13.7.2. Cyclic Peptides
13.7.3. Aliphatic Acids
13.7.4. Benzamides
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Histone Deacetylase (HDAC) Inhibitor Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Histone Deacetylase (HDAC) Inhibitor Market: Market Share Analysis
14.2. Histone Deacetylase (HDAC) Inhibitor Distributors and Customers
14.3. Histone Deacetylase (HDAC) Inhibitor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celgene
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Celleron Therapeutics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CrystalGenomics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Acetylon Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Envivo Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
